10:28 AM ET
8-K
Investor Presentation
Corbus Pharmaceuticals Holdings Investor Presentation
Corbus Pharmaceuticals updated its corporate investor presentation to highlight its clinical pipeline in oncology and obesity. Key focus areas include the CRB-701 Nectin-4 ADC, which is entering a registrational Phase 2 study for OPSCC, and CRB-913, a CB1 inverse agonist for obesity with a Phase 2 study expected to start in the first half of 2027.